Advances in the development of KRAS inhibitors

Pasi Jänne, MD, PhD, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, discusses the latest developments in targeting KRAS-mutant cancers. The approval of sotorasib and adagrasib for patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) has made a significant impact on the treatment landscape. Current KRAS inhibitors may also have potential in gastrointestinal cancers, where G12D inhibitors can target certain subtypes of pancreatic cancer. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.